Medicine and Dentistry

1. Adenocarcinoma 61%
2. Adjuvant Chemoradiotherapy 16%
3. Adjuvant Therapy 25%
4. Adverse Event 7%
5. Analysis 32%
6. Chemoradiotherapy 6%
7. Chemotherapy 36%
8. Chemotherapy Regimens 25%
9. Cohort Analysis 10%
10. Esophageal Adenocarcinoma 57%
11. Esophageal Cancer 40%
12. Esophagectomy 34%
13. Esophagus 28%
14. Esophagus Carcinoma 25%
15. Experience 25%
16. Fluorodeoxyglucose F 18 25%
17. Fluorouracil 5%
18. Glucose 25%
19. Hazard Ratio 48%
20. Hospital 5%
21. Long Term Survival 6%
22. Lymph Node 33%
23. Medical Research 25%
24. Metastatic Carcinoma 5%
25. Mixed Tumor 14%
26. Neoadjuvant Chemotherapy 86%
27. Neoadjuvant Therapy 30%
28. Neoplasm 83%
29. Pathologist 6%
30. Patient 100%
31. PET-MRI 25%
32. Positron Emission Tomography-Computed Tomography 44%
33. Postoperative Complication 7%
34. Primary Tumor 13%
35. Proportional Hazards Model 13%
36. Recurrent Disease 42%
37. Specimen 26%
38. Stomach Adenocarcinoma 33%
39. Stomach Tumor 6%
40. Surgical Margin 57%
41. Survival Analysis 7%
42. Therapeutic Procedure 30%
43. Tumor Recurrence 6%
44. Tumor Regression 24%